Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosomal PD-L1 and miRNA as Biomarkers for Immunotherapy in NSCLC
NCT04427475Unknown
- Sponsor
- Fudan University
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of pembrolizumab and nivolumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Fudan University. Primary endpoints: PD-L1 expression profiles of exosomes at 1 year and miRNA expression profiles of exosomes at 1 year. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04427475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04427475.